Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2870Carcinoma, Non-Small-Cell Lung 2420Breast Neoplasms 2065Colorectal Neoplasms 1239Neoplasm Metastasis 1223Prostatic Neoplasms 1076Melanoma 972Multiple Myeloma 960Ovarian Neoplasms 899Recurrence 849Leukemia, Myeloid, Acute 807Lung Neoplasms 756Pancreatic Neoplasms 750Lymphoma, Non-Hodgkin 726Lymphoma 660Stomach Neoplasms 622Carcinoma, Hepatocellular 564Carcinoma, Renal Cell 544Squamous Cell Carcinoma of Head and Neck 525Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 449Glioblastoma 435Advanced Solid Tumors 430Small Cell Lung Carcinoma 408Triple Negative Breast Neoplasms 407Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 367Advanced Solid Tumor 349

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Nephrotic Syndrome × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡